As Parkinson’s cases are increasing, competition is underway to deal with the effects of the disease – and researchers have identified a possible source of relief.
New studies from San Francisco (UCSF) University of California have found that a psychodelic compound found in some mushrooms has been found in some mushrooms to improve the mood, knowledge and motor symptoms of Parkinson.
This substance is often known as “magic mushrooms”, before being shown to alleviate frustration and anxiety, which encouraged researchers to explore the possibility of parkinson.
Health experts quote ‘downside’ of uncontrollable use as in the Booking of the psychicadelic retreat reported 183% spike
According to a UCSF press release, people suffering from neurological movement disorder often suffer from “weak mood unemployment” and do not see good reactions to traditional antidepressants.
Patients in some mushrooms have been shown to improve the mood, knowledge and motor symptoms of patients with Parkinson of Sicylosyabin Parkinson. (Estock)
“Many people do not realize this, but the symptoms of Parkinson’s mood are linked to the rapid physical decline,” the Relief’s Assistant Professor of the translational psychedelic research program in the release and associate director Elten Bradley, the author of the lead study.
“And they actually have a strong prophecy of patients’ living quality with Parkinson than their motor signs”
Small studies include 12 light to moderate of Parkinson’s disease. They were between 40 and 75 years old. Everyone had disappointment and/or anxiety.
FDA rejected MDMA as a psychoadelic-based treatment for mental health, PTSD
They all got 10 mg-dose silosabin, then 25 mg-dose after two weeks. To measure the effects, the participants met with the licensed therapist before and after the medicine.
In the follow-up of a week and one month, patients have reported “clinically significant improvement” in motor function not only in mood and knowledge.
“Many people do not understand it, but the symptoms of Parkinson’s mood are associated with the rapid physical decline.”
“These results are really encouraging,” Bradley told Fox News Digital. “Disappointment and anxiety, which refuses so many people with Parkinson, have improved significantly – and these improvements have been for at least three months after taking drugs for patients.”
Amir Inamdar, a pharmaceutical physician in the UK and Chief Medical Officer of Cybean, mentioned that the improvement of motor symptoms was a bit surprising.
“As writers notes, it may be due to the correction of dopamine through the effect of silosibin on several serotonin receptors.” (Was not involved in the study of Inamdar.)
According to researchers, the most common side effects of Sicylosybin were anxiety, nausea, headache and advanced blood pressure, but no one was serious enough for medical care.
Persons with neurological movement disorder often suffer from “weak mood worklessness” and do not see good reactions to the traditional antidepressants. (Estock)
Inamdar mentioned, “Despite the news of the challenging experience among some participants, Sicylosyabin seemed to be well tolerated.” “Side effects were consistent with other studies that were shown, without the rainfall/ intensity of psychological symptoms.”
Published in neuropsochophmocology, which was funded by a nature publishing, an anonymous donor.
Restrictions and further research
According to the USCF, this was the first survey to measure the effects of psychadechic substances on patients with neurodizer
Although this study was an “important first step”, Bradley mentioned that researchers could not decide from it, as it was a small pilot without a control group.
Click here to get Fox News app
“We have now started a much larger trial designed to strictly examine the silosbin in Parkison,” he told Fox News Digital.
“We are also collecting multimodal biological information to understand how silosabin works. It is also criticized for guiding the next generation of psychedelics in the pipeline, not only for the sicylosybin treatment.”
Click here to sign up for our health newsletter
Bradley still recommends that Parkinson’s patients go to Sicylosyabin and other psychadeloes with “lots of caution”.
“I would not recommend to my patients with Parkinson that they started using silosabin,” he clearly said. “We are very early in this study, and we don’t think these drugs will be safe for everyone suffering from illness.”
According to the USCF, this was the first survey to measure the effects of psychadechic substances on patients with neurodizer (Estock)
“I hope people continue to suggest the study so we can speed up this process of detecting the right psychadelic treatment for the right patient at the right time.”
Inmadar agreed that when the results were encouraging, the study was based on a small and limited sample.
For further health articles, see www.foxnews.com/health
“The study was also open-lable, which gave itself nds on the effects of high expectations, although the improvement of mood and anxiety symptoms still showed in three months,” he added.
“Overall, [the] The quite encouraging results guarantee further investigation, of course, trying to understand the process behind the improvement of motor symptoms. “
Leave a Reply